With their clinical success in COVID-19 vaccine formulations, lipid nanoparticles (LNPs) have moved to the forefront as a delivery vehicle for mRNA vaccines and therapies. The quality and efficacy of these therapies can be directly impacted by the LNP formulation, and as such, its attributes must be monitored carefully. Confident detection of LNP raw materials and related impurities based on a combination of CAD and HRAM-MS using UHPLC Hypersil GOLD C8 LC Column
